Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Parabilis Medicines paid$0.00 Mil more to buy back shares than it received from issuing new shares.
It spent$3.08 Mil paying down its debt.
It received$67.43 Mil more from issuing preferred shares than it paid to buy back preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$0.03 Mil on other financial activities.
In all, Parabilis Medicinesearned$64.38 Mil on financial activities for the
six
months ended in Dec. 2025.
Parabilis Medicines (NAS:PBLS) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Parabilis Medicines's issuance of stock for the
six
months ended in Dec. 2025 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Parabilis Medicines's repurchase of stock for the
six
months ended in Dec. 2025 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Parabilis Medicines's net issuance of debt for the
six
months ended in Dec. 2025 was $-3.08 Mil.
Parabilis Medicines spent$3.08 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Parabilis Medicines's net issuance of preferred for the
six
months ended in Dec. 2025 was $67.43 Mil.
Parabilis Medicines received$67.43 Mil more from issuing preferred shares than it paid to buy back preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Parabilis Medicines's cash flow for dividends for the
six
months ended in Dec. 2025 was $0.00 Mil.
Parabilis Medicines received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Parabilis Medicines's other financing for the
six
months ended in Dec. 2025 was $0.03 Mil.
Parabilis Medicines received$0.03 Mil on other financial activities.
Parabilis Medicines Cash Flow from Financing Related Terms
Parabilis Medicines Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Cash Flow from Financing Chart
Parabilis Medicines Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Parabilis Medicines's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $64.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $64.38 Mil mean?
Parabilis Medicines (PBLS) has a Cash Flow from Financing of $64.38 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Parabilis Medicines and its competitors.
Is Parabilis Medicines' Cash Flow from Financing too high?
Parabilis Medicines' current Cash Flow from Financing is $64.38 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Cash Flow from Financing compare to IDYA and ELVN?
Parabilis Medicines' Cash Flow from Financing of $64.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Parabilis Medicines and its competitors. Parabilis Medicines's current Cash Flow from Financing is $64.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Cash Flow from Financing of $64.38 Mil. The current Cash Flow from Financing is $64.38 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Cash Flow from Financing is $64.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
